May 26, 2026

The Real Cost of Medication Non-Adherence and How to Calculate It for Your Portfolio

Most commercial teams in pharma know that medication non-adherence is a problem. Fewer have sat down and calculated what it is actually costing their specific products, in real numbers, right now. That calculation is worth doing, and this piece is designed to help you do it.

The global figures are striking enough on their own. Pharmaceutical companies forfeit an estimated $637 billion globally each year to medication non-adherence, according to research conducted by Capgemini Consulting and HealthPrize Technologies, with US-based losses alone reaching $250 billion annually. Revenue losses equivalent to 50 to 60 percent of total annual drug sales in the US are attributed to patients not filling prescriptions or not taking their medications as prescribed. And yet, when commercial and brand teams sit down to allocate budget mid-year, patient support investment is often the first line to get cut rather than the first to get protected.

The reason for that pattern is not malice or ignorance. It is a measurement problem. The revenue that non-adherence destroys is invisible in most commercial reporting systems because it never appears in the first place. You cannot see revenue that was never generated. And budget decisions get made on the basis of what you can see.

This piece is designed to make that invisible number visible for your portfolio, so that the conversation about patient support investment can be grounded in the same commercial logic that governs every other budget decision.

Understanding What Non-Adherence Actually Costs a Brand

Before getting to the calculation framework, it is worth being precise about what non-adherence actually means commercially, because the industry uses several terms interchangeably that describe different problems with different financial consequences.

Adherence, sometimes called compliance, refers to whether a patient takes their medication correctly in terms of dose, timing, and instructions during the period they are on therapy. A patient who is on therapy but consistently taking their medication at the wrong time or in the wrong dose is non-adherent even if they appear on prescription data as an active user.

Persistence refers to how long a patient stays on therapy before stopping altogether. A patient who discontinues treatment after three months when they were prescribed a twelve-month course is non-persistent. This is the dimension that tends to have the largest commercial impact, because it determines the total number of prescriptions a patient generates over the course of their treatment.

Primary non-adherence refers to patients who receive a prescription but never fill it at all. This is a significant problem in specialty medications, where prescription abandonment rates can reach 30 to 40 percent, meaning that between a third and nearly half of all prescriptions written for high-value therapies are never collected.

Each of these dimensions contributes to the total revenue gap in different ways, and interventions that address one may not address the others. A commercial team that measures only refill rates, for example, is not seeing the full picture of what non-adherence is costing their brand.

The Five Financial Consequences That Non-Adherence Creates

Non-adherence affects a brand's commercial performance through five distinct mechanisms, and understanding all five is necessary to build a complete picture of the cost.

The first and most direct is lost prescription volume. Every dose not taken, every refill not collected, and every prescription not filled represents direct revenue that was never generated. For a product with a monthly prescription value of €3,000 and a 50 percent one-year persistence rate, half of all patients have stopped generating revenue within twelve months of their first prescription.

The second is shortened patient lifetime value. The commercial value of a patient is determined not just by the cost of a single prescription but by the total number of prescriptions they generate over the course of their treatment. A patient who persists on therapy for twenty-four months is worth approximately twice as much as one who discontinues at twelve months. Interventions that extend persistence even modestly, by six to eight weeks on average across a population, can generate substantial aggregate revenue at scale.

The third is prescriber confidence erosion. Physicians who observe patients struggling with side effects, expressing confusion about their therapy, or discontinuing treatment quickly form views about a product's real-world performance that differ from its clinical trial profile. Those views influence prescribing behaviour. A product that generates poor real-world persistence, even if clinical trial data is strong, will gradually lose prescriber confidence in ways that are difficult to recover. This is one of the most underappreciated long-term commercial consequences of non-adherence.

The fourth is health technology assessment and market access impact. As we discussed in our piece on the EU Joint Clinical Assessment, national Health Technology Assessment bodies across Europe are increasingly requiring evidence of real-world effectiveness alongside clinical trial data. A product whose real-world persistence data shows significant early discontinuation is making a weaker case for its reimbursement value than one whose patients stay on therapy and report positive treatment experiences. Non-adherence does not just cost revenue today. It weakens the evidence base that determines pricing and access tomorrow.

The fifth is brand reputation and market share vulnerability. In competitive therapeutic areas, patients who discontinue one product frequently switch to a competitor rather than restarting. Non-adherence that goes unaddressed becomes a competitive vulnerability, creating churn that transfers revenue directly to rival brands.

A Practical Framework for Calculating the Non-Adherence Cost in Your Portfolio

The following framework is designed to give commercial teams a working estimate of the revenue impact of non-adherence for a specific product, using data that most brand teams already have access to or can reasonably estimate.

The calculation has four steps.

The first step is to establish your current adherence baseline. Using pharmacy refill data, Medication Possession Ratio (MPR) data, or proportion of days covered (PDC) data from your market access or outcomes research team, establish the current one-year persistence rate for your product. Industry benchmarks suggest that approximately 50 percent of patients with chronic conditions remain on therapy after twelve months, but rates vary significantly by therapeutic area. Specialty biologics in immunology and oncology tend to have higher persistence than oral medications for cardiology or metabolic conditions, but even within specialty areas there is significant variation.

The second step is to calculate your total addressable patient population and their aggregate annual prescription value. Take the number of active patients on your product at any given time, multiply by the average annual prescription revenue per patient, and this gives you your current revenue base. Now apply your persistence rate. If 40 percent of patients discontinue within twelve months and your average patient generates €24,000 in annual prescription revenue, you are losing €9,600 per discontinuing patient. Multiply across your active patient population to get the aggregate annual revenue gap.

The third step is to model the revenue impact of modest adherence improvement. Research from Capgemini and HealthPrize found that increasing adherence rates by just ten percentage points generates $41 billion in revenue opportunity for manufacturers in the US alone. For an individual product, the ZS Associates analysis of adherence and revenue found that products with the lowest Medication Possession Ratio in their respective markets would increase their dispensed quantity and associated revenue by an average of 10 percent if they improved compliance to the market average. Apply a conservative 5 to 10 percent improvement scenario to your persistence rate and calculate the aggregate revenue that would be recovered.

The fourth step is to factor in the compounding effects. A patient who persists on therapy for six months longer than average does not just generate six additional months of prescription revenue. They are also more likely to generate real-world evidence data, more likely to become a positive reference for their prescribing physician, and less likely to switch to a competitor. These downstream effects are harder to quantify precisely but can be estimated by looking at the relationship between persistence duration and repeat prescribing behaviour in your existing patient data.

The total picture that emerges from this four-step calculation is almost always larger than commercial teams expect, because most planning models focus on new patient acquisition rather than retention, and they therefore systematically undervalue the revenue that is quietly eroding through non-adherence in the existing patient base.

Where the Revenue Goes and Why the First Ninety Days Matter Most

One of the most consistent findings in adherence research is that the risk of discontinuation is not evenly distributed across a patient's treatment journey. It is heavily concentrated in the first ninety days after the first prescription.

This is the period when patients are most uncertain about whether the therapy is working, most likely to experience unexpected side effects without adequate support to interpret them, and most likely to feel the sense of abandonment that research from XO Life has identified as one of the primary drivers of early discontinuation, with 60 percent of patients reporting feeling left alone during their treatment.

For commercial teams, this concentration of discontinuation risk has an important practical implication. Interventions that focus on the first ninety days deliver disproportionate commercial returns compared to those that focus on the broader treatment journey, because this is where the largest volume of patients is lost and where timely, personalised support has the greatest opportunity to change behaviour.

A patient support program that successfully extends average persistence from ninety days to six months does not just recover revenue for those three additional months. It changes the entire trajectory of a patient's treatment journey and significantly increases the probability that they will reach twelve months and beyond, where persistence rates begin to stabilise.

What Patient Support Investment Actually Costs Versus What It Returns

The ROI case for patient support investment is stronger than most internal planning models reflect, and the reason it is frequently underestimated is the same measurement problem that makes non-adherence costs invisible: the returns are distributed across time and across multiple functions in ways that do not always map cleanly to a single budget line.

A comprehensive systematic review of 64 studies found that 66 percent of adherence-focused patient support program interventions reported statistically significant improvement in adherence outcomes. The HUMIRA Complete patient support program analysis, which tracked patients over 36 months, found that 69 percent of program participants remained on therapy at twelve months compared to 55 percent of controls, with the difference persisting through the full 36-month follow-up period. For a product with a monthly prescription value of €2,000, a 14 percentage point improvement in twelve-month persistence across a population of 10,000 patients represents €33.6 million in additional annual revenue, before accounting for the compounding effects of extended persistence and improved prescriber confidence.

Research published in PharmExec examining the ROI of specialty pharmacy patient support programs found that programs achieving 7 to 10 percent higher Medication Possession Ratios than retail channels, and 50 to 60 percent twelve-month persistence compared to 30 to 40 percent in unsupported channels, generated returns that substantially exceeded the cost of program delivery. Broader analysis suggests that leading patient support programs achieve 15 to 40 percent ROI through reduced prescription abandonment, extended treatment duration, and market share protection.

The investment required to deliver meaningful patient support has also changed significantly with the emergence of integrated health platforms. The cost of building and maintaining a standalone branded patient support application, which we discussed in detail in an earlier piece in this series, runs from €500,000 to €2 million in development alone before ongoing maintenance, content production, and regulatory compliance costs. An integrated platform model that delivers structured, personalised patient support within a health ecosystem that patients are already using reduces that investment substantially while generating higher engagement, better persistence data, and more credible real-world evidence as a byproduct.

The Calculation Your Budget Meeting Needs

To bring this down to a number that is useful in a mid-year budget conversation, here is the simplest version of the adherence revenue calculation that most commercial teams can run with the data they already have.

Take your current active patient number. Multiply by average annual prescription revenue per patient. Multiply by your current non-persistence rate, meaning the proportion of patients who discontinue within twelve months. That is your current annual revenue gap from non-adherence. Now calculate what a 10 percent improvement in persistence would generate. That is your revenue opportunity from patient support investment, against which any investment in patient engagement infrastructure should be evaluated.

For a product with 20,000 active patients, average annual prescription revenue of €18,000 per patient, and a 45 percent twelve-month discontinuation rate, the current annual revenue gap is €162 million. A 10 percent improvement in persistence recovers €16.2 million annually. A patient support program that costs €2 million per year to deliver and generates that improvement has an ROI of over 700 percent, before accounting for the downstream effects on prescriber confidence, real-world evidence quality, and competitive market share protection.

Those numbers will vary significantly by product, therapeutic area, and patient population. But the structure of the calculation is consistent, and the output almost always produces a figure that is substantially larger than the budget being allocated to address it.

What Commercial Teams Should Be Asking Right Now

The mid-year budget review is the right moment to ask three questions that most commercial teams are not yet asking systematically.

The first is: what is our current twelve-month persistence rate and how does it compare to the market average for our therapeutic area? If your product's persistence is below the market average, that gap represents both a patient experience problem and a recoverable revenue opportunity that deserves a line in the commercial plan.

The second is: where in the treatment journey are patients most likely to discontinue, and what are the primary reasons? The answer to this question determines what kind of intervention will have the most impact. If patients are discontinuing in the first ninety days because of unmanaged side effects, the investment priority is structured side effect support and rapid clinical access. If they are discontinuing because of complexity or confusion about whether the therapy is working, the priority is education and progress tracking. Getting the diagnosis right before allocating budget is as important in commercial strategy as it is in clinical medicine.

The third is: what would a 10 percent improvement in persistence be worth to this brand, and is that number larger than the budget we are currently allocating to patient support? For most brands, the answer to the second part of that question is yes, often significantly so, and that gap between the value of the opportunity and the investment being made to capture it is the commercial case for patient support that belongs in every mid-year budget review.

Non-adherence is not a patient behaviour problem that sits outside the commercial plan. It is a revenue problem that sits at the centre of it. The brands that start measuring it that way, and allocating resources accordingly, are the ones that will look back in three years and wonder why they waited so long.

Discover how brite supports pharmaceutical companies in building the patient relationships that protect and grow brand revenue at xo-life.com/en/brite